The average P/S ratio for HAE's competitors is 3.66, providing a benchmark for relative valuation. Haemonetics Corp Corp (HAE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -3.70%, this premium appears unsustainable.